文献速递淋巴瘤

剂量调整EPOCH-R方案治疗伴MYC重排的初治侵袭性弥漫大B细胞淋巴瘤:一项前瞻性、多中心、单臂2期研究

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
PubMed 文献 · Lancet Haematol · 2018-01-01

这项前瞻性、多中心、单臂2期研究纳入53例伴MYC重排的初治侵袭性B细胞淋巴瘤患者,接受DA-EPOCH-R联合中枢神经系统预防治疗6个周期。中位随访55.6个月后,48个月无事件生存率为71.0%,总生存率为76.7%;4级中性粒细胞减少见于53%的周期,治疗相关死亡3例(均为感染)。作者认为DA-EPOCH-R可产生持久缓解,应考虑用于这类疾病的治疗。

要点

  • 53例伴MYC重排的初治侵袭性B细胞淋巴瘤患者接受DA-EPOCH-R方案治疗6个周期。
  • 48个月无事件生存率71.0%(95%CI 56.5-81.4),总生存率76.7%(95%CI 62.6-86.1)。
  • 4级中性粒细胞减少见于53%的周期,治疗相关死亡3例(均为感染)。

核心结论

  • 作者认为,DA-EPOCH-R在伴MYC重排的侵袭性B细胞淋巴瘤患者中产生持久缓解,应考虑用于这些疾病的治疗。

研究设计与样本

  • 前瞻性、多中心、单臂2期研究,纳入53例伴MYC重排的初治侵袭性B细胞淋巴瘤患者。
  • DA-EPOCH-R计划联合中枢神经系统预防治疗6个周期,主要终点包括无事件生存率和总生存率。
  • 研究注册于ClinicalTrials.gov(NCT01092182)。

主要发现

  • 患者中位年龄61岁(范围29-80;IQR 50-70);43例(81%)为III-IV期疾病,26例(49%)为高-中危或高危国际预后指数(IPI)评分。
  • 19例为确认的单纯MYC重排(单打击),24例同时伴BCL2、BCL6或两者重排(双打击),两组特征相似。
  • 中位随访55.6个月(IQR 50.5-61.1)后,全部患者48个月无事件生存率为71.0%(95%CI 56.5-81.4),48个月总生存率为76.7%(95%CI 62.6-86.1)。
  • 毒性包括4级中性粒细胞减少见于160/301个周期(53%),4级血小板减少见于40个周期(13%),任何级别发热伴中性粒细胞减少见于56个周期(19%)。
  • 治疗相关死亡3例,均为感染。

临床怎么用

  • 作者认为,DA-EPOCH-R应考虑用于伴MYC重排的侵袭性B细胞淋巴瘤的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment. We aimed to determine the outcome of dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R), an intensive infusional treatment regimen, in untreated aggressive B-cell lymphoma with MYC rearrangement. METHODS: We present the final analysis of a prospective, multicentre, single-arm, phase 2 study of DA-EPOCH-R in patients with untreated aggressive B-cell lymphoma with MYC rearrangement. DA-EPOCH-R was scheduled to be administered with CNS prophylaxis for six cycles. Primary endpoints included event-free and overall survival. This study is registered with ClinicalTrials.gov (NCT01092182). FINDINGS: 53 patients were enrolled, with median age of 61 years (range 29-80; IQR 50-70); 43 (81%) patients had stage III-IV disease and 26 (49%) had high-intermediate or high international prognostic index (IPI) scores. 19 patients had confirmed MYC rearrangement alone (single-hit) and 24 also had rearrangement of BCL2, BCL6, or both (double-hit), with similar characteristics between these two groups. After a median follow-up of 55·6 months (IQR 50·5-61·1), 48-month event-free survival was 71·0% (95% CI 56·5-81·4) and 48-month overall survival was 76·7% (95% CI 62·6-86·1) for all patients. Toxicity included grade 4 neutropenia in 160 (53%) of 301 cycles, grade 4 thrombocytopenia in 40 (13%) cycles, and any grade of fever with neutropenia in 56 (19%) cycles. There were three treatment-related deaths (all infections). INTERPRETATION: In this study, DA-EPOCH-R produced durable remission in patients with MYC-rearranged aggressive B-cell lymphomas and should be considered for the treatment of these diseases. FUNDING: Cancer Trials Support Unit and Center for Cancer Research of the National Cancer Institute and Genentech.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018. PMID: 30501868. doi:10.1016/S2352-3026(18)30177-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。